Vistin Pharma ASA Statistics
Vistin Pharma ASA (0RAM) Stock Statistics & Valuation Metrics
Total Valuation
Vistin Pharma ASA has a market cap or net worth of NOK 858.07M. The enterprise value is NOK 798.37M.
- Market Cap
- NOK 858.07M
- Enterprise Value
- NOK 798.37M
Share Statistics
Vistin Pharma ASA has 44,344,593 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 44,344,593
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Vistin Pharma ASA’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- -832.43K
- Employee Count
- 74
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Vistin Pharma ASA had revenue of ― and earned -61.60M in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- 206.75M
- Operating Income
- -82.30M
- Pretax Income
- ―
- Net Income
- -61.60M
- EBITDA
- 27.79M
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- -0.04
- 52-Week Price Change
- -9.09%
- 50-Day Moving Average
- 19.01
- 200-Day Moving Average
- 20.23
- Relative Strength Index (RSI)
- 25.45
- Average Volume (3m)
- 511
Important Dates
Vistin Pharma ASA upcoming earnings date is Feb 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 12, 2027
- Ex-Dividend Date
- ―
Balance Sheet
Vistin Pharma ASA has ― in cash and marketable securities with NOK 0.00 in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- NOK 0.00
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Vistin Pharma ASA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- -5.20%
- EPS Growth Forecast
- -19.82%

